Needham & Company LLC Reaffirms Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Needham & Company LLC reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $320.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on ALNY. TD Cowen raised their price […]
More Stories
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have received a consensus rating of “Moderate Buy” from...
Contrasting RCM Technologies (NASDAQ:RCMT) and YY Group (NASDAQ:YYGH)
RCM Technologies (NASDAQ:RCMT – Get Free Report) and YY Group (NASDAQ:YYGH – Get Free Report) are both small-cap business services...
Teekay Tankers (NYSE:TNK) Research Coverage Started at StockNews.com
StockNews.com started coverage on shares of Teekay Tankers (NYSE:TNK – Free Report) in a research note published on Thursday. The...
Shell (NYSE:SHEL) Price Target Cut to $80.00 by Analysts at Scotiabank
Shell (NYSE:SHEL – Free Report) had its price objective reduced by Scotiabank from $90.00 to $80.00 in a research note...
Retractable Technologies (NYSE:RVP) Coverage Initiated at StockNews.com
StockNews.com initiated coverage on shares of Retractable Technologies (NYSE:RVP – Free Report) in a report released on Thursday. The firm...
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)
StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report published on Thursday. The brokerage...